Jessica Bjerk
Acute Care · San Antonio, TXNPI 1639452931
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,500 of the $19,547 with a category attached, or 69.1%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 86.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $8,530 and has fallen 96.5% since, to $295 in 2025. Among acute care clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $118.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$17K
- Alnylam Pharmaceuticals Inc.$900
- Merck$527
- Novartis$198
- AstraZeneca$192
- Johnson & Johnson$153
- plus $661 from 13 others
What the payments were for
- Speaking & faculty fees$13,50069%
- Travel & lodging$2,31312%
- Food & beverage$3,73419%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 43 | $16,916 |
| Alnylam Pharmaceuticals Inc. | 26 | $900 |
| Merck | 34 | $527 |
| Novartis | 12 | $198 |
| AstraZeneca | 9 | $192 |
| Johnson & Johnson(2 entities) | 8 | $153 |
| Boehringer Ingelheim | 6 | $115 |
| Impulse Dynamics (USA) Inc. | 4 | $90 |
| Cvrx, Inc. | 2 | $74 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Biotronik Inc. | 2 | $58 |
| Tactile Systems Technology Inc | 3 | $44 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Pfizer | 2 | $33 |
| Lilly USA, LLC | 1 | $21 |
| Abbott | 1 | $18 |
| Chiesi USA, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,547 in reported general payments places this provider in the 95th percentile of 2,323 acute care providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $118,301 |
| XareltoRivaroxaban | 96 | $110,305 |
| JardianceEmpagliflozin | 50 | $47,996 |
| EntrestoSacubitril/Valsartan | 38 | $47,289 |
| FarxigaDapagliflozin Propanediol | 59 | $44,461 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $11,299 |
| Nebivolol Hcl | 100 | $3,605 |
| Dofetilide | 19 | $3,596 |
| Prasugrel Hcl | 49 | $3,177 |
| Metoprolol Succinate | 182 | $3,004 |
| Ezetimibe | 51 | $2,692 |
| Valsartan | 75 | $2,602 |
| SotalolSotalol Hcl | 112 | $2,041 |
| Nifedipine ErNifedipine | 46 | $1,998 |
| Rosuvastatin Calcium | 135 | $1,739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $118,301105 claims |
| Johnson & JohnsonXarelto | $153 | $110,30596 claims |
| Boehringer IngelheimJardiance | $115 | $47,99650 claims |
| NovartisEntresto | $198 | $47,28938 claims |
| AstraZenecaFarxiga | $192 | $44,46159 claims |
| Esperion Therapeutics, Inc.Nexlizet | $67 | $11,29914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,323 acute care providers in Texas.
Other acute care in San Antonio
- Christie MorrisonSan Antonio$225K
- Tara CummingSan Antonio$12K
- Erin HernandezSan Antonio$10K
- Daniel ChristensenSan Antonio$8K
- Jill FolkertSan Antonio$8K
- Jennifer PilotteDallas$232K
- Amanda BradleyDallas$85K
- Laura WilsonEl Paso$32K
- Kim HuynhCypress$29K
- Martha LibertyDallas$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.